Loading stock data…
Picard Medical, Inc. (PMI)
$0.16+0.01 (+9.33%)
Market ClosedLast close Jun 29
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Picard Medical, Inc. in the Healthcare sector is trading at $0.16 with a market capitalization of $29M. The stock is currently near its 52-week low of $0.11, remaining 94.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.15M↑ | $1.01M↓ | $1.19M↓ | $2.13M↑ | $620,000 |
| Gross Profit | $275,000↓ | $411,000↑ | -$130,000↓ | -$127,000↑ | -$358,000 |
| Operating Income | -$4.51M↓ | -$3.00M↑ | -$3.49M↑ | -$3.52M↓ | -$3.25M |
| Net Income | -$7.62M↓ | -$4.29M↑ | -$10.43M↓ | -$6.72M↓ | -$5.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
2006.70%
Volume
Today's trading volume
2.61M
Recent News
Philip Morris' IQOS Retains FDA Modified-Risk Authorization
Philip Morris wins renewed FDA backing for IQOS, keeping its modified-risk claims alive as the company accelerates its shift beyond cigarettes.
PMI Q4 Earnings Call Highlights
Precigen’s leadership team outlined rapid early commercialization progress for its recently approved therapy PAPZIMEOS during a Wednesday, March 25, 2026, update call covering fourth-quarter and full-year 2025 results. Management said the company has shifted from being primarily an R&D organizat
Picard Medical enters agreement for $50m senior secured notes
Picard Medical plans to issue $15m in notes at closing, with option to fund an additional $35m.
Picard Medical (PMI): Assessing Valuation After Share Expansion and Dilution Concerns Spark Sell-Off
Picard Medical (PMI) shares saw a steep drop after the company disclosed an expansion of its equity incentive plan, increasing the available shares to 18 million and adding warrants. This led to immediate concerns over shareholder dilution. See our latest analysis for Picard Medical. The dramatic 59.77% plunge in Picard Medical's share price over a single day put a spotlight on dilution risks. The company’s year-to-date share price return remains positive at 15.69%. Recent events such as the...
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks rose late Friday afternoon with the NYSE Health Care Index and the Health Care Se